JP2024524933A5 - - Google Patents

Info

Publication number
JP2024524933A5
JP2024524933A5 JP2023577688A JP2023577688A JP2024524933A5 JP 2024524933 A5 JP2024524933 A5 JP 2024524933A5 JP 2023577688 A JP2023577688 A JP 2023577688A JP 2023577688 A JP2023577688 A JP 2023577688A JP 2024524933 A5 JP2024524933 A5 JP 2024524933A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
isomer
hydrate
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524933A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/099018 external-priority patent/WO2022262784A1/zh
Publication of JP2024524933A publication Critical patent/JP2024524933A/ja
Publication of JP2024524933A5 publication Critical patent/JP2024524933A5/ja
Pending legal-status Critical Current

Links

JP2023577688A 2021-06-15 2022-06-15 Idh変異体阻害剤およびその使用 Pending JP2024524933A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110661394.5 2021-06-15
CN202110661394 2021-06-15
PCT/CN2022/099018 WO2022262784A1 (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Publications (2)

Publication Number Publication Date
JP2024524933A JP2024524933A (ja) 2024-07-09
JP2024524933A5 true JP2024524933A5 (https=) 2025-06-23

Family

ID=84526875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577688A Pending JP2024524933A (ja) 2021-06-15 2022-06-15 Idh変異体阻害剤およびその使用

Country Status (10)

Country Link
US (1) US20240208978A1 (https=)
EP (1) EP4356914A4 (https=)
JP (1) JP2024524933A (https=)
KR (1) KR20240021774A (https=)
CN (1) CN117460512A (https=)
AU (1) AU2022294860A1 (https=)
BR (1) BR112023024454A2 (https=)
CA (1) CA3217608A1 (https=)
MX (1) MX2023013664A (https=)
WO (1) WO2022262784A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035776A1 (en) * 2024-08-05 2026-02-12 Frontier Medicines Corporation Pi3k-alpha binding compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd 2−アミノ置換8−オキソジヒドロプリン誘導体
PL2900675T3 (pl) * 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
JP6387360B2 (ja) * 2013-03-14 2018-09-05 ノバルティス アーゲー 変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン
MA46064B1 (fr) * 2014-09-19 2020-04-30 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
US9624175B2 (en) * 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2764523T3 (es) * 2015-07-27 2020-06-03 Lilly Co Eli Compuestos de 7-feniletilamino-4H-pirimido[4,5-D][1,3]oxazin-2-ona y su uso como inhibidores de IDH1 mutantes
CN109311863B (zh) 2016-06-06 2021-10-29 伊莱利利公司 突变型idh1抑制剂
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
ES2941631T3 (es) 2016-12-16 2023-05-24 Lilly Co Eli Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors

Similar Documents

Publication Publication Date Title
JP2024516371A5 (https=)
JP2021063088A5 (https=)
JP2024071370A5 (https=)
JP2021191784A5 (https=)
JP2023512175A5 (https=)
JP2025013344A5 (https=)
ES2295009T3 (es) Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar.
JP2022191257A5 (https=)
JP2018517686A5 (https=)
JP2022502500A5 (https=)
JP2017528503A5 (https=)
JP2017528507A5 (https=)
JP7091477B2 (ja) エダラボン医薬組成物
JP2025161856A5 (https=)
JP2017531619A5 (https=)
TW201247613A (en) Ester derivatives of bimatoprost compositions and methods
JP2013500977A5 (https=)
JP2022538817A5 (https=)
JP2019536812A5 (https=)
JP2022531251A5 (https=)
JP2024516359A5 (https=)
JP2021534160A5 (https=)
JP2022551691A5 (https=)
JP2009517411A5 (https=)
JP2025502064A5 (https=)